These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24430787)

  • 1. Clinical predictors of atheroma progression despite optimal glycemic control in early-stage diabetic patients with coronary artery disease: Insight from the DIANA study.
    Kataoka Y; Yasuda S; Miyamoto Y; Sase K; Kosuge M; Kimura K; Yoshimasa Y; Miyazaki S;
    J Atheroscler Thromb; 2014; 21(5):509-18. PubMed ID: 24430787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients.
    Kataoka Y; Yasuda S; Miyamoto Y; Sase K; Kosuge M; Kimura K; Yoshimasa Y; Miyazaki S;
    Circ J; 2012; 76(3):712-20. PubMed ID: 22240597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atheroma Progression in Obese Early-stage Diabetic Japanese Patients in Response to Glycemic Control: Sub-analysis from the DIANA Study.
    Kataoka Y; Yasuda S; Miyamoto Y; Sase K; Kosuge M; Kimura K; Yoshimasa Y; Miyazaki S;
    J Atheroscler Thromb; 2015 Jul; 22(7):697-705. PubMed ID: 25737191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus.
    Kataoka Y; Shao M; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ
    Eur J Prev Cardiol; 2013 Apr; 20(2):209-17. PubMed ID: 22345692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
    Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
    Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low serum docosahexaenoic acid is associated with progression of coronary atherosclerosis in statin-treated patients with diabetes mellitus: results of the treatment with statin on atheroma regression evaluated by intravascular ultrasound with virtual histology (TRUTH) study.
    Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Sato A; Nozato T; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Terashima M; Michishita I
    Cardiovasc Diabetol; 2014 Jan; 13():13. PubMed ID: 24410834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of continuous glucose monitoring-guided glycemic control on progression of coronary atherosclerosis in type 2 diabetic patients with coronary artery disease: The OPTIMAL randomized clinical trial.
    Kataoka Y; Kitahara S; Funabashi S; Makino H; Matsubara M; Matsuo M; Omura-Ohata Y; Koezuka R; Tochiya M; Tamanaha T; Tomita T; Honda-Kohmo K; Noguchi M; Maruki M; Kanai E; Murai K; Iwai T; Sawada K; Matama H; Honda S; Fujino M; Yoneda S; Takagi K; Otsuka F; Asaumi Y; Hosoda K; Nicholls SJ; Yasuda S; Noguchi T
    J Diabetes Complications; 2023 Oct; 37(10):108592. PubMed ID: 37741088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
    Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
    Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of lowering postprandial glucose level on cardiovascular outcomes in early-stage diabetic patients with coronary artery disease: 10-year post-trial follow-up analysis of the DIANA study.
    Kataoka Y; Yasuda S; Asaumi Y; Honda S; Noguchi T; Miyamoto Y; Sase K; Iwahashi N; Kawamura T; Kosuge M; Kimura K; Takamisawa I; Iwanaga Y; Miyazaki S
    J Diabetes Complications; 2023 May; 37(5):108469. PubMed ID: 36996727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic control is independently associated with rapid progression of coronary atherosclerosis in the absence of a baseline coronary plaque burden: a retrospective case-control study from the PARADIGM registry.
    Won KB; Lee BK; Lin FY; Hadamitzky M; Kim YJ; Sung JM; Conte E; Andreini D; Pontone G; Budoff MJ; Gottlieb I; Chun EJ; Cademartiri F; Maffei E; Marques H; de Araújo Gonçalves P; Leipsic JA; Lee SE; Shin S; Choi JH; Virmani R; Samady H; Chinnaiyan K; Berman DS; Narula J; Shaw LJ; Bax JJ; Min JK; Chang HJ
    Cardiovasc Diabetol; 2022 Nov; 21(1):239. PubMed ID: 36371222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
    Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
    J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
    Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
    Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
    Califf RM; Boolell M; Haffner SM; Bethel M; McMurray J; Duggal A; Holman RR;
    Am Heart J; 2008 Oct; 156(4):623-32. PubMed ID: 18946890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound.
    Kataoka Y; Shao M; Wolski K; Uno K; Puri R; Murat Tuzcu E; Hazen SL; Nissen SE; Nicholls SJ
    Atherosclerosis; 2014 Feb; 232(2):377-83. PubMed ID: 24468151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal assessment of coronary plaque volume change related to glycemic status using serial coronary computed tomography angiography: A PARADIGM (Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging) substudy.
    Won KB; Lee SE; Lee BK; Park HB; Heo R; Rizvi A; Lin FY; Kumar A; Hadamitzky M; Kim YJ; Sung JM; Conte E; Andreini D; Pontone G; Budoff MJ; Gottlieb I; Chun EJ; Cademartiri F; Maffei E; Marques H; Leipsic JA; Shin S; Choi JH; Virmani R; Samady H; Chinnaiyan K; Raff GL; Stone PH; Berman DS; Narula J; Shaw LJ; Bax JJ; Min JK; Chang HJ
    J Cardiovasc Comput Tomogr; 2019; 13(2):142-147. PubMed ID: 30580992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of glycemic variability and glycated hemoglobin as risk factors of coronary artery disease in patients with undiagnosed diabetes.
    Mi SH; Su G; Li Z; Yang HX; Zheng H; Tao H; Zhou Y; Tian L
    Chin Med J (Engl); 2012 Jan; 125(1):38-43. PubMed ID: 22340463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
    Salas M; Ward A; Caro J
    Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy: a prospective observational study.
    Kuroda M; Shinke T; Sakaguchi K; Otake H; Takaya T; Hirota Y; Sugiyama D; Nakagawa M; Hariki H; Inoue T; Osue T; Taniguchi Y; Iwasaki M; Nishio R; Kinutani H; Konishi A; Hiranuma N; Takahashi H; Terashita D; Hirata KI
    JACC Cardiovasc Interv; 2015 May; 8(6):800-811. PubMed ID: 25999102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL).
    Kataoka Y; Hosoda K; Makino H; Matsubara M; Matsuo M; Ohata Y; Koezuka R; Tamanaha T; Tomita T; Honda-Kohmo K; Noguchi M; Son C; Nishimura K; Asaumi Y; Miyamoto Y; Noguchi T; Yasuda S
    Cardiovasc Diagn Ther; 2019 Oct; 9(5):431-438. PubMed ID: 31737515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.